Novavax confirms efficacy against U.K., South African SARS-CoV-2 strains

By The Science Advisory Board staff writers

March 15, 2021 -- Novavax's SARS-CoV-2 vaccine candidate NVX-CoV2373 has a 96.4% efficacy against mild, moderate, and severe disease caused by the original COVID-19 strain, the company's phase III trial found.

The vaccine has an 86.3% efficacy against the B.1.1.7/501Y.V1 variant circulating in the U.K. Additionally, a phase IIB trial demonstrated a 55.4% efficacy against the COVID-19 South African variant, B.1.351, among the HIV-negative trial participants.

In both trials, NVX-CoV2373 demonstrated 100% protection against severe disease, including hospitalization and death.

The firm plans to use the data to serve as the basis for submission to various regulatory agencies worldwide authorizing the vaccine's use, Novavax said.


Copyright © 2021 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.